Minerva Neurosciences, Inc (NASDAQ:NERV) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus target price of $17.00 for the company, according to Zacks. Zacks has also given Minerva Neurosciences an industry rank of 163 out of 265 based on the ratings given to related companies.

Several research analysts have recently commented on the company. Zacks Investment Research upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Thursday, March 30th. Jefferies Group LLC assumed coverage on Minerva Neurosciences in a report on Monday, March 6th. They issued a “buy” rating and a $17.00 price objective on the stock. ValuEngine upgraded Minerva Neurosciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 23rd. Finally, JMP Securities reiterated an “outperform” rating and issued a $20.00 price objective (up previously from $17.00) on shares of Minerva Neurosciences in a report on Thursday, June 1st.

WARNING: “Minerva Neurosciences, Inc (NERV) Given $17.00 Average Target Price by Brokerages” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/06/29/minerva-neurosciences-inc-nerv-given-17-00-average-target-price-by-brokerages.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its position in Minerva Neurosciences by 1.0% in the first quarter. ClariVest Asset Management LLC now owns 29,200 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 300 shares in the last quarter. TD Asset Management Inc. increased its position in Minerva Neurosciences by 1.3% in the first quarter. TD Asset Management Inc. now owns 27,100 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 357 shares in the last quarter. Bank of New York Mellon Corp increased its position in Minerva Neurosciences by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 80,201 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 1,286 shares in the last quarter. Teachers Advisors LLC increased its position in Minerva Neurosciences by 7.4% in the first quarter. Teachers Advisors LLC now owns 31,226 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 2,141 shares in the last quarter. Finally, AQR Capital Management LLC increased its position in Minerva Neurosciences by 24.0% in the fourth quarter. AQR Capital Management LLC now owns 34,521 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 6,675 shares in the last quarter. Hedge funds and other institutional investors own 70.33% of the company’s stock.

Shares of Minerva Neurosciences (NASDAQ NERV) traded up 10.06% on Thursday, hitting $8.75. The stock had a trading volume of 1,930,142 shares. The company’s market capitalization is $321.16 million. The company has a 50-day moving average of $8.71 and a 200 day moving average of $9.30. Minerva Neurosciences has a 52 week low of $6.50 and a 52 week high of $14.92.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported ($0.30) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.30). On average, equities research analysts predict that Minerva Neurosciences will post ($1.50) EPS for the current year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Get a free copy of the Zacks research report on Minerva Neurosciences (NERV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.